Navigation Links
Pharmasset Reports Fiscal First Quarter 2009 Financial Results
Date:2/9/2009

Phase 1 studies with PSI-7851 in the first quarter of 2009;

-- Report interim results from INFORM-1 trial in second quarter of 2009;

-- Report interim results from 28 day add-on study with R7128 in non-responder, HCV genotype 2 and genotype 3 patients in first half of 2009;

-- Report interim results from 28 day add-on study with R7128 in treatment naive, HCV genotype 1 patients in first half of 2009;

-- Report phase 1 antiviral data with PSI-7851 in second half of 2009.

About Pharmasset

Pharmasset is a clinical stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe, among other countries. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial. Pharmasset also anticipates initiating phase 1 studies with its second generation nucleotide inhibitor for HCV, PSI-7851 in the first quarter of 2009.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

    Contact
    Richard E. T. Smith, Ph.D.
    VP, Investor Relations and Corporate Communications
    '/>"/>
SOURCE Pharmasset, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Pharmasset Announces $45.5 Million Registered Direct Offering of Common Stock
2. Pharmasset and Roche Obtain FDA Consent to Start a Phase 2b Study With R7128 in Treatment Naive HCV Patients
3. Pharmasset to Present at Two Upcoming Investor Conferences
4. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
5. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
6. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
7. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
8. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
9. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
10. Pharmasset Joins Russell 3000 Index
11. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/2/2015)... -- GOJO, inventors of PURELL ® Advanced Hand ... the White House Forum.  GOJO was among 150 major ... at the White House Forum to announce commitments over ... antibiotic-resistant bacteria, detect resistant strains, preserve the efficacy of ... infections. "A primary prevention approach to reduce ...
(Date:6/2/2015)... June 2, 2015 MGB ... antibiotic resistance problem  MGB Biopharma, a ... anti-infectives, to address the major global problem of ... a stable intravenous (IV) formulation of MGB-BP-3, designed for ... infections.  The intravenous formulation of MGB-BP-3 ...
(Date:6/2/2015)... 02, 2015 GenoCAD , a ... improve protein expression, announced the formation of its new ... and entrepreneurs with a broad range of experience in ... The team includes: , Jimmy Roussel, Entrepreneur in Residence ... a background in technology and marketing. He has served ...
(Date:6/1/2015)... , June 1, 2015  Turing Pharmaceuticals ... Eliseo Oreste Salinas , MD, MSc,  has joined ... Dr. Salinas, who holds a medical ... brings a record of significant accomplishments in the ... Dr. Salinas has played a leadership ...
Breaking Biology Technology:GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 2GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 3GOJO Among Leaders At The White House Forum On Antibiotic Stewardship 4MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 2MGB Biopharma Succeeds in Developing an IV Formulation of MGB-BP-3 for the Treatment of Systemic Susceptible and Resistant Gram-Positive Hospital-Acquired Infections 3GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 2GenoCAD Announces New Board of Advisors, Improves Protein Expression Using Custom Gene Synthesis 3Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 2Turing Pharmaceuticals Names Eliseo Salinas, MD and MSc, President of Research and Development 3
... Boston University engineers have designed cells that can count and ... of genes are activated in a specific order. , Such ... used to count the number of times a cell divides, ... also serve as biosensors that count exposures to different toxins. ...
... with unique QTRAP(R) technologyMONTREAL, May 28 Caprion ... with Applied Biosystems, a division of Life Technologies ... the verification and validation of protein biomarker candidates ... is extending its leadership in mass spectrometry-based biomarker ...
... general health and self-care management by using simple tools ... May 28 Roche, the maker of ACCU-CHEK(R) blood ... availability of two new tools that can help patients ... impact on their blood glucose levels, giving them greater ...
Cached Biology Technology:MIT, BU engineer cellular circuits that count events 2MIT, BU engineer cellular circuits that count events 3Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation 2Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation 3Caprion Proteomics Inc. and Applied Bioystems Work Together to Accelerate Protein Biomarker Verification and Validation 4Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 2Roche Announces Back-to-Basics Approach to Diabetes Care - Simpler is Better 3
(Date:5/19/2015)... , May 19, 2015  Technology is rapidly ... internally and in the cloud. Passwords and their management ... of OTP and standards-based specifications such as those developed ... outmoded use of passwords presents for BYOD, COPE, IoT, ... unified biometric identity protocol. In response ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
(Date:5/7/2015)... , May 7, 2015 ... fingerprint sensors, FPC1022 and FPC1035, FPC,s smallest touch ... FPC1035 are mainly considered for integration on the ... gives smartphone OEMs increased possibilities to integrate touch ... decreased size also improves possibilities for module manufacturers ...
Breaking Biology News(10 mins):HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2FPC Introduces its Smallest Touch Fingerprint Sensors to Date 2
... the recent opening of its new Biomolecular Labeling Laboratory, ... become one of a small handful of facilities in ... different isotopes to make them easier to analyze. The ... those in biomedical fields who also want to take ...
... one can create a field of science out of thin ... bold concept. But for the emerging field of sustainability ... of potentially divergent theory, practice and policy, the gamble has ... Proceedings of the National Academy of Sciences , scientists from ...
... killing countless coral reefs around the world can now be ... researchers say. Coral researchers and reef managers will be ... allows them to classify specific diseases based on the presence ... to reduce the impact of disease on the world,s imperilled ...
Cached Biology News:Tags? We're it. NIST opens new 'biolabeling' research facility 2Is sustainability science really a science? 2Scientific sleuths pinpoint the guilty coral killers 2
High voltage electrophoresis power supply...
Rab GDP dissociation inhibitor beta...
The Programmable MP-3500P-F Power Supply can be applied for any Microfluidic application....
BD BioCoat Collagen IV 35 mm Culture Dishes, tissue-culture treated polystyrene with a uniform application of mouse collagen type IV....
Biology Products: